SCHEDULE: Arie Belldegrun Discloses 5.4% Stake in Allogene

Dr. Arie Belldegrun and affiliated entities have filed a Schedule 13G reporting a 5.4% beneficial ownership stake in Allogene Therapeutics, Inc.

Summary

• Dr. Arie Belldegrun, along with several affiliated investment entities, reported beneficial ownership of 13,466,383 shares of Allogene Therapeutics, Inc. common stock.
• This holding represents 5.4% of the company's total outstanding common stock as of March 10, 2026.
• The reported ownership includes 3,866,329 shares issuable upon the exercise of stock options exercisable within 60 days of March 31, 2026.
• The filing is a joint statement involving Dr. Belldegrun, Bellco Legacy LLC, Bellco Legacy IV LLC, Vida Ventures LLC, Vida Ventures III, L.P., and Vida Ventures III-A, L.P.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure confirming existing ownership levels rather than a change in strategic direction or financial performance.

Positives

• Continued significant investment and alignment of interest from a key insider and founder-affiliated entities.
• The reporting person maintains a substantial position, signaling long-term confidence in the company's equity.

Negatives

• None identified in this ownership disclosure filing.

Risks

• Concentration of voting power among a small group of affiliated entities.
• Potential for market volatility if significant holders decide to divest portions of their holdings.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a regulatory disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by founders or major institutional investors in the biotechnology sector are standard practice to maintain transparency regarding significant equity positions and do not typically signal immediate strategic shifts.

Comparison to Industry Standards

• The filing adheres to standard SEC requirements for reporting beneficial ownership exceeding 5% of a public company's equity.
• The structure of the filing, including the Joint Filing Agreement, is consistent with standard practices for affiliated investment vehicles.

Stakeholder Impact

• Provides transparency to shareholders regarding the concentration of ownership among key insiders and affiliated investment firms.

Next Steps

• Continued monitoring of future Form 4 or 13G/A filings for any changes in the reporting persons' positions.

Key Dates

Keywords

Allogene Therapeutics, Schedule 13G, Arie Belldegrun, Beneficial Ownership, Biotech, Insider Holdings